Short Interest in PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Grows By 82.3%

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 26,800 shares, a growth of 82.3% from the February 28th total of 14,700 shares. Based on an average daily volume of 17,700 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.4% of the shares of the stock are sold short.

PharmaCyte Biotech Stock Down 4.3 %

Shares of NASDAQ PMCB opened at $1.32 on Monday. The stock’s 50-day simple moving average is $1.63 and its two-hundred day simple moving average is $1.69. The firm has a market capitalization of $9.06 million, a P/E ratio of 2.49 and a beta of -0.25. PharmaCyte Biotech has a twelve month low of $1.29 and a twelve month high of $2.55.

PharmaCyte Biotech (NASDAQ:PMCB) last released its earnings results on Monday, March 17th. The company reported ($0.10) earnings per share for the quarter.

PharmaCyte Biotech Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.